| Product NDC: | 0781-2052 |
| Proprietary Name: | Terazosin Hydrochloride |
| Non Proprietary Name: | Terazosin Hydrochloride |
| Active Ingredient(s): | 2 mg/1 & nbsp; Terazosin Hydrochloride |
| Administration Route(s): | ORAL |
| Dosage Form(s): | CAPSULE |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0781-2052 |
| Labeler Name: | Sandoz Inc |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA074823 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 19980330 |
| Package NDC: | 0781-2052-05 |
| Package Description: | 500 CAPSULE in 1 BOTTLE (0781-2052-05) |
| NDC Code | 0781-2052-05 |
| Proprietary Name | Terazosin Hydrochloride |
| Package Description | 500 CAPSULE in 1 BOTTLE (0781-2052-05) |
| Product NDC | 0781-2052 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Terazosin Hydrochloride |
| Dosage Form Name | CAPSULE |
| Route Name | ORAL |
| Start Marketing Date | 19980330 |
| Marketing Category Name | ANDA |
| Labeler Name | Sandoz Inc |
| Substance Name | TERAZOSIN HYDROCHLORIDE |
| Strength Number | 2 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Adrenergic alpha-Antagonists [MoA],alpha-Adrenergic Blocker [EPC] |